NGDN: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: NGDN

NCBI ID: G25983

NGDN

NGDN: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Neuroguidin (NGDN) is a protein that is expressed in various tissues of the brain and is known for its role in the development and progression of neurodegenerative diseases. One of its functions is to interact with the protein EIF4E (endoplasmic reticulum-associated protein 4E), which is a transmembrane protein that is involved in the transport of various proteins to the endoplasmic reticulum.

Recent studies have identified NGDN as a potential drug target and biomarker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This is because NGDN has been shown to play a role in the misfolding and aggregation of beta-amyloid peptides, which are a hallmark of these disorders.

NGDN has also been shown to interact with other proteins that are involved in the development and progression of neurodegenerative diseases. For example, NGDN has been shown to interact with the protein Tau, which is involved in the development of Alzheimer's disease. Additionally, NGDN has been shown to interact with the protein Phosphatidylserine, which is involved in the formation of beta-amyloid plaques and the progression of neurodegenerative diseases.

NGDN is also a potential biomarker for neurodegenerative diseases, as its levels have been shown to be decreased in individuals with certain disorders. This suggests that NGDN may be a useful diagnostic or therapeutic target for these disorders.

In conclusion, NGDN is a protein that has the potential to be a drug target and biomarker for various neurological disorders. Its interaction with the protein EIF4E and other proteins involved in the development and progression of neurodegenerative diseases makes it an attractive target for research and development of new treatments for these disorders. Further studies are needed to fully understand the role of NGDN in neurodegenerative diseases and to determine its potential as a drug target and biomarker.

Protein Name: Neuroguidin

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome. Its dissociation from the complex determines the transition from state pre-A1 to state pre-A1* (PubMed:34516797). Inhibits mRNA translation in a cytoplasmic polyadenylation element (CPE)-dependent manner (By similarity)

The "NGDN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NGDN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets